References: -
- Osuchowski MF, Winkler MS, Skirecki T, et al. The COVID-19 puzzle
deciphering pathophysiology and phenotypes of a new disease entity.
Lancet Respir Med. 2021;9(6):622–642.
- Venet F, Cour M, Rimmele T, et al. Longitudinal assessment of IFN-I
activity and immune profile in critically ill COVID-19 patients with
acute respiratory distress syndrome. Crit Care. 2021;25(1):140.
- Remy KE, Mazer M, Striker DA, et al. Severe immunosuppression and not
a cytokine storm characterizes COVID-19 infections. JCI Insight.
2020;5(17).
- NIH. COVID-19 treatment guidelines panel. coronavirus disease 2019
(COVID-19) treatment guidelines (2020). Available at: https://www.
covid19treatmentguidelines.nih.gov/.
- Ni L, Ye F, Cheng ML, Feng Y, Deng YQ, Zhao H, et al. Detection of
SARSCoV-2-Specific humoral and cellular immunity in COVID-19
convalescent individuals. Immunity (2020) 52(6):971–77.e3. doi:
10.1016/j.immuni.2020.04.023
- Ghizlane EA, Manal M, Abderrahim EK, Abdelilah E, Mohammed M, Rajae A,
et al. Lymphopenia in covid-19: A single center retrospective study of
589 cases. Ann Med Surg (2021) 69:102816. doi:
10.1016/j.amsu.2021.102816
- Lee J, Park SS, Kim TY, Lee DG, Kim DW. Lymphopenia as a biological
predictor of outcomes in COVID-19 patients: A nationwide cohort study.
Cancers (Basel) (2021) 13(3):471. doi: 10.3390/cancers13030471
- Ramljak D, Vukoja M, Curlin M, Vukojevic K, Barbaric M, Glamoclija U,
et al. Early response of CD8+ T cells in COVID-19 patients. J Pers Med
(2021) 11 (12):1291. doi: 10.3390/jpm11121291
- He R, Lu Z, Zhang L, Fan T, Xiong R, Shen X, et al. The clinical
course and its correlated immune status in COVID-19 pneumonia. J Clin
Virol (2020) 127:104361. doi: 10.1016/j.jcv.2020.104361
- Chen Z, John Wherry E. T Cell responses in patients with COVID-19. Nat
Rev Immunol (2020) 20(9):529–36. doi: 10.1038/s41577-020-0402-6
- Suryawanshi, P., Takbhate, B., Athavale, P., Jali, P., Memane, N.,
Mirza, S., Karandikar, M., Kakrani, A. L., Kanitkar, S., Gandham, N.,
Barthwal, M. S., Dole, S., Chaturvedi, S., Pawale, S., Tripathy, A.,
Bhawalkar, J. S., & Tripathy, S. (2023). Lymphopenia with Altered T
Cell Subsets in Hospitalized COVID-19 Patients in Pune,
India. Viral immunology , 36 (3), 163–175.
https://doi.org/10.1089/vim.2022.0123
- Fathi N, Rezaei N. Lymphopenia in COVID-19: Therapeutic opportunities.
Cell Biol Int (2020) 44(9):1792–7. doi: 10.1002/cbin.11403
- Schultheiß C, Paschold L, Simnica D, Mohme M, Willscher E, von
Wenserski L, et al. Next-generation sequencing of T and b cell
receptor repertoires from COVID-19 patients showed signatures
associated with severity of disease. Immunity (2020) 53(2):442–55.e4.
doi: 10.1016/j.immuni.2020.06.024
- Sekine T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, Gorin JB,
Olsson A, et al. Robust T cell immunity in convalescent individuals
with asymptomatic or mild COVID-19. Cell (2020) 183(1):158–68.e14.
doi: 10.1016/j.cell.2020.08.017
- Wilk AJ, Rustagi A, Zhao NQ, Roque J, Martı́nez-Colón GJ, McKechnie JL,
et al. A single-cell atlas of the peripheral immune response in
patients with severe COVID-19. Nat Med (2020) 26(7):1070–6. doi:
10.1038/s41591-020-0944-y
- Li S, Zhang Y, Guan Z, Li H, Ye M, Chen X, et al. SARS-CoV-2 triggers
inflammatory responses and cell death through caspase-8 activation.
Signal Transduct Target Ther (2020) 5(1):235. doi:
10.1038/s41392-020-00334-0
- Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers
associated with COVID-19 disease progression. Crit Rev Clin Lab Sci
(2020) 57(6):389–99. doi: 10.1080/10408363.2020.1770685
- Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and
immunological features of severe and moderate coronavirus disease
2019. J Clin Invest (2020) 130(5):2620–9. doi: 10.1172/JCI137244
- Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical
characteristics of coronavirus disease 2019 in China. N Engl J Med
(2020) 382 (18):1708–20. doi: 10.1056/NEJMoa2002032
- Zhang S, Asquith B, Szydlo R, Tregoning JS, Pollock KM, et al.
Peripheral T cell lymphopenia in COVID-19: Potential mechanisms and
impact. Immunother Adv (2021) 1(1):ltab015. doi:
10.1093/immadv/ltab015
- Bao J, Li C, Zhang K, Kang H, Chen W, Gu B. Comparative analysis of
laboratory indexes of severe and non-severe patients infected with
COVID-19. Clin Chim Acta (2020) 509:180–94. doi:
10.1016/j.cca.2020.06.009
- Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of
immune response in patients with coronavirus 2019 (COVID-19) in wuhan,
China. Clin Infect Dis (2020) 71(15):762–8. doi: 10.1093/cid/ciaa248
- Kalfaoglu B, Almeida-Santos J, Tye C.A, Satou Y, Ono M. T-Cell
hyperactivation and paralysis in severe COVID-19 infection revealed by
singlecell analysis. Front Immunol (2020) 11. doi:
10.3389/fimmu.2020.589380
- Zingaropoli MA, Perri V, Pasculli P, Cogliati Dezza F, Nijhawan P,
Savelloni G, et al. Major reduction of NKT cells in patients with
severe COVID-19 pneumonia. Clin Immunol (2021) 222:108630. doi:
10.1016/j.clim.2020.108630
- Kreutmair S, Unger S, Núñez NG, Ingelfinger F, Alberti C, De Feo D, et
al. Distinct immunological signatures discriminate severe COVID-19
from non- SARS-CoV-2-driven critical pneumonia. Immunity (2021)
54(7):1578–93.e5. doi: 10.1016/j.immuni.2022.01.015
- Jouan Y, Guillon A, Gonzalez L, Perez Y, Boisseau C, Ehrmann S, et al.
Phenotypical and functional alteration of unconventional T cells in
severe COVID-19 patients. J Exp Med (2020) 217(12):e20200872.
- Gong F, Dai Y, Zheng T, Cheng L, Zhao D, Wang H, et al. Peripheral
CD4+ T cell subsets and antibody response in COVID-19 convalescent
individuals. J Clin Invest (2020) 130(12):6588–99. doi:
10.1172/JCI141054
- Sekine T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, Gorin JB,
Olsson A, et al. Robust T cell immunity in convalescent individuals
with asymptomatic or mild COVID-19. Cell (2020) 183(1):158–68.e14.
doi: 10.1016/j.cell.2020.08.017
- Kundu R, Narean JS, Wang L, Fenn J, Pillay T, Fernandez ND, et al.
Crossreactive memory T cells associate with protection against
SARS-CoV-2 infection in COVID-19 contacts. Nat Commun (2022) 13(1):80
doi: 10.1038/s41467-021-27674-x.
- Kared H, Redd AD, Bloch EM, Bonny TS, Sumatoh H, Kairi F, et al.
SARSCoV- 2-specific CD8+ T cell responses in convalescent COVID-19
individuals. J Clin Invest (2021) 131(5):e145476:e145476. doi:
10.1172/JCI145476
- Cohen KW, Linderman S.L, Moodie Z, Czartoski J, Lai L, Mantus G, et
al. Longitudinal analysis shows durable and broad immune memory after
SARS-CoV-2 infection with persisting antibody responses and memory b
and T cells. medRxiv (2021) 2(7):100354. doi:
10.1016/j.xcrm.2021.10035
- Cao W-C, Liu W, Zhang P-H, Zhang F, Richardus JH. Disappearance of
antibodies to SARS-associated coronavirus after recovery. N Engl J Med
(2007) 357 (11):1162–3. doi: 10.1056/NEJMc070348
- Ng O-W, Chia A, Tan AT, Jadi RS, Leong HN, Bertoletti A, et al. Memory
T cell responses targeting the SARS coronavirus persist up to 11 years
post-infection. Vaccine (2016) 34(17):2008–14. doi:
10.1016/j.vaccine.2016.02.063
- MacLeod MKL, Kappler JW, Marrack P. Memory CD4 T cells: generation,
reactivation and re-assignment. Immunology (2010) 130(1):10–5. doi:
10.1111/j.1365-2567.2010.03260.x
- Farber DL, Yudanin NA, Restifo NP. Human memory T cells: generation,
compartmentalization and homeostasis. Nat Rev Immunol (2014)
14(1):24–35. doi:10.1038/nri3567
- Tian Y, Babor M, Lane J, Schulten V, Patil VS, Seumois G, et al.
Unique phenotypes and clonal expansions of human CD4 effector memory T
cells re-expressing CD45RA. Nat Commun (2017) 8(1):1473. doi:
10.1038/s41467-017-01728-5
- Graham N, Eisenhauer P, Diehl SA, Pierce KK, Whitehead SS, Durbin AP,
et al. Rapid induction and maintenance of virus-specific CD8(+)
T(EMRA) and CD4(+) T(EM) cells following protective vaccination
against dengue virus challenge in humans. Front Immunol (2020) 11:479.
doi: 10.3389/ fimmu.2020.00479
- Govender M, Hopkins FR, Göransson R, Svanberg C, Shankar EM, Hjorth M,
Nilsdotter-Augustinsson Å, Sjöwall J, Nyström S and Larsson M (2022) T
cell perturbations persist for at least 6 months following
hospitalization for COVID-19. Front. Immunol. 13:931039.
doi:10.3389/fimmu.2022.931039
- Bonifacius A, Tischer-Zimmermann S, Dragon AC, Gussarow D, Vogel A,
Krettek U, et al. COVID-19 immune signatures reveal stable antiviral T
cell function despite declining humoral responses. Immunity (2021)
54(2):340–54.e6. doi: 10.1016/j.immuni.2021.01.008
- Zenarruzabeitia O, Astarloa-Pando G, Terrén I, Orrantia A, Pérez-Garay
R, Seijas-Betolaza I, et al. T Cell Activation, Highly armed cytotoxic
cells and a shift in monocytes CD300 receptors expression is
characteristic of patients with severe COVID-19. Front Immunol (2021)
12. doi: 10.3389/fimmu.2021.655934
- Le Bert N, Tan A.T, Kunasegaran K, Tham C.Y.L, Hafezi M, Chia A, et
al. SARS-cov-2-specific t cell immunity in cases of covid-19 and sars,
and uninfected controls. Nature (2020) 584(7821):457–62. doi:
10.1038/s41586-020-2550-z
- Björkander S, Du L, Zuo F, Ekström S, Wang Y, Wan H, et al.
SARS-CoV-2- specific b- and T-cell immunity in a population-based
study of young Swedish adults. J Allergy Clin Immunol (2022)
149(1):65–75.e8. doi: 10.1016/j.jaci.2021.10.014
- Kalfaoglu B, Almeida-Santos J, Tye CA, Satou Y, Ono M. T-Cell
dysregulation in COVID-19. Biochem Biophys Res Commun (2021)
538:204–10. doi: 10.1016/j.bbrc.2020.10.079
- Zuo J, DowellA.C, Pearce H, Verma K, Long HM, Begum J, et al. Robust
SARSCoV- 2-specificT cell immunity is maintained at 6months following
primary infection. Nat Immunol (2021) 22(5):620–6. doi:
10.1038/s41590-021-00902-8
- Long QX, Li Q.L, Deng Q, Yuan H.J, J, et al. Clinical and
immunological assessment of asymptomatic SARS-CoV-2 infections. Nat
Med (2020) 26(8):1200– 4. doi: 10.1038/s41591-020-0965-6
- Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C,
Hausner MA, et al. Rapid decay of anti–SARS-CoV-2 antibodies in
persons with mild covid-19. N Engl J Med (2020) 383(11):1085–7. doi:
10.1056/ NEJMc2025179
- Sherina N, Piralla A, Du L, Wan H, Kumagai-Braesch M, réll J, et al.
Persistence of SARS-CoV-2-specific B and T cell responses in
convalescent COVID-19 patients 6–8 months after the infection. Med
(2021) 2(3):281–95.e4.doi: 10.1016/j.medj.2021.02.001
- Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al.
Immunological memory to SARS-CoV-2 assessed for up to 8 months after
infection. Science (2021) 371(6529):eabf4063. doi:
10.1126/science.abf4063
- Muecksch F, Weisblum Y, Barnes C.O, Schmidt F, Schaefer-Babajew D,
Wang Z, et al. Affinity maturation of SARS-CoV-2 neutralizing
antibodies confers potency, breadth, and resilience to viral escape
mutations. Immunity (2021) 54 (8):1853–68.e7. doi:
10.1016/j.immuni.2021.07.008
- Aleem A, Akbar Samad AB, Slenker AK. Emerging variants of SARS-CoV-2
and novel therapeutics against coronavirus (COVID-19), in StatPearls.
Treasure Island FL: StatPearls Publishing, Copyright © 2022,
StatPearls Publishing LLC (2022).
- Carfì A, Bernabei R, Landi F. Persistent symptoms in patients after
acute COVID-19. JAMA (2020) 324(6):603–5. doi:
10.1001/jama.2020.12603
- Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month
consequences of COVID-19 in patients discharged from hospital: A
cohort study. Lancet (2021) 397(10270):220–32. doi:
10.1016/S0140-6736(20)32656-8
- Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of
COVID-19. Nat Med (2022) 28:583–90. doi: 10.1038/s41591-022-01689-3